Cargando…

Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada

BACKGROUND: Early in the coronavirus disease 2019 (COVID-19) pandemic, before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines became available, it was hypothesized that BCG (Bacillus Calmette–Guérin), which stimulates innate immunity, could provide protection against SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Pépin, Jacques, Labbé, Annie-Claude, Carignan, Alex, Parent, Marie-Elise, Yu, Jennifer, Grenier, Cynthia, Beauchemin, Stéphanie, De Wals, Philippe, Valiquette, Louis, Rousseau, Marie-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354805/
https://www.ncbi.nlm.nih.gov/pubmed/34493410
http://dx.doi.org/10.1016/j.vaccine.2021.08.019
_version_ 1783736656364306432
author Pépin, Jacques
Labbé, Annie-Claude
Carignan, Alex
Parent, Marie-Elise
Yu, Jennifer
Grenier, Cynthia
Beauchemin, Stéphanie
De Wals, Philippe
Valiquette, Louis
Rousseau, Marie-Claude
author_facet Pépin, Jacques
Labbé, Annie-Claude
Carignan, Alex
Parent, Marie-Elise
Yu, Jennifer
Grenier, Cynthia
Beauchemin, Stéphanie
De Wals, Philippe
Valiquette, Louis
Rousseau, Marie-Claude
author_sort Pépin, Jacques
collection PubMed
description BACKGROUND: Early in the coronavirus disease 2019 (COVID-19) pandemic, before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines became available, it was hypothesized that BCG (Bacillus Calmette–Guérin), which stimulates innate immunity, could provide protection against SARS-CoV-2. Numerous ecological studies, plagued by methodological deficiencies, revealed a country-level association between BCG use and lower COVID-19 incidence and mortality. We aimed to determine whether BCG administered in early life decreased the risk of SARS-CoV-2 infection in adulthood and the severity of COVID-19. METHODS: This case-control study was conducted in Quebec, Canada. Cases were patients with a positive SARS-CoV-2 nucleic acid amplification test performed at two hospitals between March–October 2020. Controls were identified among patients with non-COVID-19 samples processed by the same microbiology laboratories during the same period. Enrolment was limited to individuals born in Quebec between 1956 and 1976, whose vaccine status was accessible in a computerized registry of 4.2 million BCG vaccinations. RESULTS: We recruited 920 cases and 2123 controls. Fifty-four percent of cases (n = 424) and 53% of controls (n = 1127) had received BCG during childhood (OR: 1.03; 95% CI: 0.89–1.21), while 12% of cases (n = 114) and 11% of controls (n = 235) had received two or more BCG doses (OR: 1.14; 95% CI: 0.88–1.46). After adjusting for age, sex, material deprivation, recruiting hospital and occupation there was no evidence of protection conferred by BCG against SARS-CoV-2 (AOR: 1.01; 95% CI: 0.84–1.21). Among cases, 77 (8.4%) needed hospitalization and 18 (2.0%) died. The vaccinated were as likely as the unvaccinated to require hospitalization (AOR: 1.01, 95% CI: 0.62–1.67) or to die (AOR: 0.85, 95% CI: 0.32–2.39). CONCLUSIONS: BCG does not provide long-term protection against symptomatic COVID-19 or severe forms of the disease.
format Online
Article
Text
id pubmed-8354805
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-83548052021-08-11 Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada Pépin, Jacques Labbé, Annie-Claude Carignan, Alex Parent, Marie-Elise Yu, Jennifer Grenier, Cynthia Beauchemin, Stéphanie De Wals, Philippe Valiquette, Louis Rousseau, Marie-Claude Vaccine Article BACKGROUND: Early in the coronavirus disease 2019 (COVID-19) pandemic, before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines became available, it was hypothesized that BCG (Bacillus Calmette–Guérin), which stimulates innate immunity, could provide protection against SARS-CoV-2. Numerous ecological studies, plagued by methodological deficiencies, revealed a country-level association between BCG use and lower COVID-19 incidence and mortality. We aimed to determine whether BCG administered in early life decreased the risk of SARS-CoV-2 infection in adulthood and the severity of COVID-19. METHODS: This case-control study was conducted in Quebec, Canada. Cases were patients with a positive SARS-CoV-2 nucleic acid amplification test performed at two hospitals between March–October 2020. Controls were identified among patients with non-COVID-19 samples processed by the same microbiology laboratories during the same period. Enrolment was limited to individuals born in Quebec between 1956 and 1976, whose vaccine status was accessible in a computerized registry of 4.2 million BCG vaccinations. RESULTS: We recruited 920 cases and 2123 controls. Fifty-four percent of cases (n = 424) and 53% of controls (n = 1127) had received BCG during childhood (OR: 1.03; 95% CI: 0.89–1.21), while 12% of cases (n = 114) and 11% of controls (n = 235) had received two or more BCG doses (OR: 1.14; 95% CI: 0.88–1.46). After adjusting for age, sex, material deprivation, recruiting hospital and occupation there was no evidence of protection conferred by BCG against SARS-CoV-2 (AOR: 1.01; 95% CI: 0.84–1.21). Among cases, 77 (8.4%) needed hospitalization and 18 (2.0%) died. The vaccinated were as likely as the unvaccinated to require hospitalization (AOR: 1.01, 95% CI: 0.62–1.67) or to die (AOR: 0.85, 95% CI: 0.32–2.39). CONCLUSIONS: BCG does not provide long-term protection against symptomatic COVID-19 or severe forms of the disease. The Author(s). Published by Elsevier Ltd. 2021-12-08 2021-08-11 /pmc/articles/PMC8354805/ /pubmed/34493410 http://dx.doi.org/10.1016/j.vaccine.2021.08.019 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pépin, Jacques
Labbé, Annie-Claude
Carignan, Alex
Parent, Marie-Elise
Yu, Jennifer
Grenier, Cynthia
Beauchemin, Stéphanie
De Wals, Philippe
Valiquette, Louis
Rousseau, Marie-Claude
Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
title Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
title_full Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
title_fullStr Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
title_full_unstemmed Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
title_short Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
title_sort does bcg provide long-term protection against sars-cov-2 infection? a case–control study in quebec, canada
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354805/
https://www.ncbi.nlm.nih.gov/pubmed/34493410
http://dx.doi.org/10.1016/j.vaccine.2021.08.019
work_keys_str_mv AT pepinjacques doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT labbeannieclaude doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT carignanalex doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT parentmarieelise doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT yujennifer doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT greniercynthia doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT beaucheminstephanie doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT dewalsphilippe doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT valiquettelouis doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada
AT rousseaumarieclaude doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada